Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB (OMX: IRLAB-A) – last patient completes treatment in pirepemat trial
Published by Arron Aatkar

IRLAB has announced that all patients enrolled in the REACT-PD trial have completed treatment and had their final follow-up visit. This Phase IIb study is evaluating IRLAB’s prefrontal cortex enhancer, pirepemat, as a potential therapy to improve balance and reduce falls in Parkinson’s disease patients. Top-line results are due to be reported in Q125, consistent with prior guided timelines for the trial.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free